• Theriva Biologics began dosing in VIRAGE2, a Phase 2a trial testing more frequent repeat dosing of VCN-01 with standard chemotherapy in first-line metastatic pancreatic cancer.
• The study aims to refine the dosing regimen for a potential future pivotal Phase 3 program, following earlier Phase 2b VIRAGE results already reported.
• VIRAGE2 will not present efficacy results now; initial safety, tolerability, and pharmacodynamic readouts are expected in Q3 2027.
• The program builds on prior data suggesting repeat dosing could improve outcomes versus chemotherapy alone, without detailing performance metrics.
• Enrollment is expected to finish in H2 2026, setting a key timing marker for the company’s pancreatic cancer strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-091674), on August 06, 2026, and is solely responsible for the information contained therein.